Gilead Sciences (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B or influenza. In 2006, Gilead acquired two companies that were developing drugs to treat patients with pulmonary diseases. The company has fourteen commercially available products. Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2009, the company had approximately 4,000 full-time employees.
Campaign Finance$985,033 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Bundled ContributionsMoney raised by the firm from multiple donors on behalf of the recipient. The firm's own contributions are not included.
Recipient Lobbyist Amount La Pac $17,500
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Gilead Sciences
Names of Lobbyists
Firm Hired Amount Gilead Sciences $10,360,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Medical Research & Clin Labs
Most Frequently Disclosed Bills
Bill No. Title H.R.1943 Tax Equity Act of 2009 H.R.822 Paget's Cancer Awareness Act H.R.822 National Right-to-Carry Reciprocity Act of 2011 H.R.6114 Virgin Islands National Park Land Acquisition Act of 2010 H.R.1943 Health Insurance Industry Fair Competition Act H.R.1429 Stop AIDS in Prison Act of 2009 S.2731 Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008 H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.822 Routine HIV/AIDS Screening Coverage Act of 2007 H.R.1943 Stop AIDS in Prison Act of 2007
RegulationsMentioned in 86 dockets; Submitted to 13 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Gilead Sciences" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Gilead Sciences
- Toggle 2 FDA Draft Guidance for Industry on Non-Penicillin Beta-Lactam Risk Assessment: A CGMP Framework; Availability 2011
- Toggle 2 HHS Interim Final Rules for Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services; etc. 2010
- Toggle 1 FDA Guidance for Industry on Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling 2006
- Toggle 1 FDA Investigational New Drug Applications; Co-Development of Investigational Drugs 2010
- Toggle 1 FDA Draft Guidance for Industry on Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment 2010
- Toggle 1 FDA Draft Guidance for Industry and Investigators on Safety Reporting Requirements for INDs and BA/BE Studies; Availability 2010
- Toggle 1 FDA Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies; Availability 2011
- Toggle 1 FDA Postmarketing Safety Reporting for Combination Products 2008
- Toggle 1 FDA Patent Term Extension Application for LETAIRIS (ambrisentan), U.S. Patent No. 5,703,017 2008
- Toggle 1 FDA Establishing Timeframes for Implementation of Product Safety Labeling Changes; Request for Comments 2011
Mentions in Document Text
View all mentions data for Gilead Sciences
- Toggle 13 FDA Investigate Polyethylene Glycol 3350 Product Safety for Use With Pediatric Patients 2012
- Toggle 12 FDA Antiviral Drugs Advisory Committee; Notice of Meeting 2012
- Toggle 10 Recognize 5-Year Exclusivity for Dienogest, the New Active Moiety in NATAZIA®, Pursuant to Sections 505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) of the FDCA 2013
- Toggle 7 FDA Patent Extension Application for Macugen (pegaptanib sodium), U.S. Patent No. 6,051,698 2005
- Toggle 6 FDA Patent Term Extension Application for LETAIRIS (ambrisentan), U.S. Patent No. 5,703,017 2008
- Toggle 6 FDA Not Approve Truvada®, a Pending Supplemental New Drug Application Submitted by Gilead Sciences, Inc. - CLOSED 2012
- Toggle 4 FDA Patent Extension Application for EMTRIVA (emtricitabine), U.S. Patent No. 5,914,331 2005
- Toggle 4 FDA Recognize 5-year Exclusivity for Each of The New Active Moieties in Stribild, Namely EVG and COBI and Make any Necessary Changes to FDA's Exclusivity Summary to Reflect an Interpretation of the Governing Statute and Regulation that Recognizes 5-year Exclusivity for all Active Moieties 2013
- Toggle 3 FDA Not Rely in Whole or in Part, and Invalidate The Recommendations Made by the Antiviral Drugs Advisory Committee on May 10, 2012 Due to Irregularities in The Last Minute Selection of Thirteen Permanenet and Temporary Members With Respect to Supplemental New Drug Application of Gilead Sciences Inc. - CLOSED 2012
- Toggle 3 FDA Patent Term Extension Application for LETAIRIS (ambrisentan), U.S. Patent No. 5,840,722 2008
Advisory Committees1 person on 1 committee
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Gilead Sciences" that sat on federal advisory committees.
- Toggle Department of Health and Human Services 1 person on 1 committee